About CRISPR Medicine News

CRISPR Medicine Becomes Reality

Since 2018, CRISPR Medicine News (CMN) has followed CRISPR's remarkable journey from pioneering technology to clinical breakthroughs, with the historic first approval of a CRISPR-based therapy in 2023.

As next-generation editing platforms enter the clinic and the field continues to advance, we provide crucial insights into this rapidly developing landscape.

Our coverage focuses on the following key areas:

  • Gene-editing tools and technology innovations
  • Delivery advances
  • In vivo gene-editing breakthroughs
  • Pre-clinical research developments
  • Clinical trial updates
  • Safety advances

We bring you perspectives from the scientists, clinicians, and industry leaders driving CRISPR Medicine forward. All our content is written by experienced and scientifically trained science writers with solid knowledge from the field, and we strive for accuracy in our reporting, with all interviewed experts reviewing their interviews before publication.

Stay informed with our CMN Weekly Newsletter highlighting the latest developments and insights in CRISPR Medicine. We provide regular Clinical Trial Updates and maintain a manually curated CRISPR Medicine News Clinical Trials register that is continuously updated to track the field's progress in real-time. Our CMN Webinars and CMN Live interviews feature leading experts discussing cutting-edge developments and answering questions from our engaged community. Our CMN Briefs and CMN Highlights are bitesize formats that keep you updated with the latest developments in the therapeutic gene-editing space.

Each year, we host the CRISPR Medicine Conference (CRISPRMED) in Copenhagen, bringing together global leaders in CRISPR medicine to share insights, forge collaborations, and advance the field.

Our Mission

To foster innovation in CRISPR Medicine by providing accessible, accurate information to the field.

Our content serves a sophisticated global audience of biopharma executives, investors, researchers, healthcare professionals and patients and their advocates, working to bring novel treatments to those who need them the most.

We’re created by COBO Technologies

CRISPR Medicine News is part of CRISPR Medicine Media Aps – founded in 2019 by Jens-Ole Bock, co-founder COBO Technologies.

CRISPR Medicine News is managed by experienced science writer and editor Karen O’Hanlon Cohrt PhD.

All content is based on well-researched and well-documented information.

Contact us

Email: theeditor@crisprmedicinenews.com

Intellectual property rights

Unless otherwise indicated, the content on the CRISPR Medicine News site is copyright of CRISPR Medicine News.

Karen O’Hanlon Cohrt, PhD

Karen O’Hanlon Cohrt, PhD

Editor in Chief

Karen joined CRISPR Medicine News in March 2020. She hails from Ireland where she obtained an Honours Bachelor Degree in Biological Sciences and a PhD in Biotechnology (graduated 2011). Karen has a strong and broad research background, developed through a decade of work in various academic and startup labs in Ireland and Denmark. During her research career, she worked with yeast, filamentous fungi, bacteria, plants, moth larvae and mammalian cells, and has tried everything from Sanger sequencing to genetically modifying disease-causing fungi.

Karen is passionate about learning, asking questions and sharing knowledge with others - attributes that motivate her to write about many aspects of science for everyone from scientists to the next-door neighbor. She enjoys being a part of CRISPR Medicine News and hopes that with her broad research background and inquisitive nature she can bring some exciting stories and stimulate interesting discussions about CRISPR with featured scientists as well as readers.

Rasmus Kragh Jakobsen

Rasmus Kragh Jakobsen

Science Editor, Co-founder

Rasmus studied biochemistry at the University of Copenhagen.

Though he has a deep affection for Drosophila and developmental biology he found an even deeper satisfaction swapping the Gilson pipette for a keyboard.

His editorial career began in 2001 as the science editor at the Danish daily Information and he has been writing and editing about science, technology, and society ever since.

 

Gorm Palmgren

Gorm Palmgren

Science Writer and Editor

Gorm has a Ph.D. in Cell Biology and has worked as a freelance science journalist since 2001. With more than 500 feature articles in magazines, books and on the web, he covers most natural and technical sciences including medicine, neurology, biotechnology, synthetic biology, computer science and technology. Moreover, he is experienced with website management, newsletter production and in-house design of scientific brochures. Gorm is member of the board in Danish Science Journalists Association.

 

Lasse V Jørgensen

Lasse V Jørgensen

Scientific Assistant

Lasse joined CRISPR Medicine News in August 2020. He has a Bachelor's degree in Biochemistry and Molecular Biology and is currently pursuing a Master's degree in Computational Biomedicine at University of Southern Denmark. Lasse is passionate about the therapeutic applications of genome editing and has hands-on experience with applying genome editing tools for the development of CAR T cells.

Mikkel Kristensen

Mikkel Kristensen

Scientific Assistant

Mikkel joined CRISPR Medicine News in March 2021. With a bachelor's degree in Biomedicine at the University of Southern Denmark and an upcoming master's degree in Business Administration and Bioentrepreneurship from Copenhagen Business School, Mikkel is always eager to learn more about the developments in gene therapies, as well as the businesses behind them. This has led to an immense interest in investing based on both the tendencies in the broader markets as well as in-depth analyses of biotech companies.

Advisors

Christina Blaagaard Collignon

Originally trained as a journalist and with a background in news reporting, Christina Blaagaard has spent over 20 years in the media through the disruption of an industry which was one of the first to be hit by the full force of digital transformation of both product and business model. She has worked in some of the biggest Danish and Scandinavian media organisations, now serving as CEO for Technologiens Mediehus. She also serves on the board of trade organisations, Danske Medier and Technology Denmark.

close
Search CRISPR Medicine